Conditions: Glaucoma Ocular Hypertension
Keywords: pediatric glaucoma pediatric ocular hypertension travoprost
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 25
Healthy volunteers: no

Brief summary:
The purpose of this study was to assess the safety and describe the steady-state plasma pharmacokinetic (PK) profiles of Travoprost ophthalmic solution, 0.004% (new formulation) following a once daily administration for 7 days in pediatric glaucoma or ocular hypertension patients.

Detailed description:

Arms:
arm 1: Travoprost ophthalmic solution, 0.004% (new formulation), one drop administered topically in the inferior cul-de-sac of the eye each morning at 9 AM (± 60 minutes) for 7 days

Interventions: intervention 1: Travoprost ophthalmic solution, 0.004% (new formulation)
Intervention descriptions: intervention 1: Travoprost ophthalmic solution, 0.004%, new formulation

Protocol document: